Loading organizations...

§ Private Profile · Milford, MA, USA
Reprieve Cardiovascular is a technology company.
Reprieve Cardiovascular aims to revolutionize Acute Heart Failure care with its automated fluid management technology for precise and improved patient outcomes.
Reprieve Cardiovascular has raised $103.0M across 2 funding rounds.
Reprieve Cardiovascular has raised $103.0M in total across 2 funding rounds.
Reprieve Cardiovascular is a development-stage medical device company headquartered in Milford, Massachusetts, focused on revolutionizing decongestion management for acute decompensated heart failure (ADHF) patients through its proprietary Reprieve System.[1][2][3][4] The system serves heart failure patients—over 25 million globally, with 8.5 million in the U.S. by 2030—by addressing congestion, the primary cause of hospitalizations (83% of cases), which leads to extended hospital stays averaging 5.8 days and suboptimal outcomes from imprecise diuretic therapy.[2][3][5] It solves the limitations of traditional diuretics, approved 60 years ago, by providing real-time physiological monitoring, automated diuretic dosing, saline replenishment to protect kidneys, and personalized recommendations to accelerate fluid and sodium removal while minimizing risks like kidney injury and readmissions.[1][2][3][5] The company demonstrates strong growth momentum, emerging from stealth in February 2024 with $42 million in Series A financing, securing $61 million in Series B to fund the FASTR II pivotal trial (first patient enrolled), achieving positive FASTR pilot results meeting efficacy and safety endpoints, and gaining FDA IDE approval.[2][3][4]
Reprieve Cardiovascular emerged from stealth mode on February 20, 2024, after raising $42 million in Series A financing co-led by Lightstone Ventures and Sante Ventures, with participation from Deerfield Management, Genesis Capital, and Arboretum Ventures.[4] While specific founders are not detailed in available sources, the company was founded as a privately held medical device firm in Milford, Massachusetts, targeting the longstanding unmet need in ADHF treatment, where diuretics lack precision due to absent real-time feedback.[1][4][5] The idea crystallized around bringing intelligence to decongestion via automated fluid management, kicking off with the FASTR pilot trial in 2022 across the U.S. and Europe to compare the Reprieve System against standard diuretic therapy.[3][4] Pivotal early traction included positive first-in-human results presented in Germany, FASTR pilot success announced with principal investigator James Udelson, M.D., from Tufts Medical Center, and FDA IDE approval for the FASTR II randomized pivotal trial, followed by $61 million in Series B financing and first-patient enrollment.[1][2][3]
Reprieve Cardiovascular rides the wave of precision medicine in cardiology, where heart failure affects 1-2% of adults worldwide and drives massive hospital burdens—congestion causes 83% of U.S. HF hospitalizations amid rising prevalence to 8.5 million U.S. patients by 2030.[2][5] Timing is ideal post-FASTR pilot and amid FDA approvals, capitalizing on market forces like escalating HF costs, clinician demand for data-driven tools beyond 60-year-old diuretics, and medtech investor interest in outpatient-shifting therapies to cut readmissions.[3][4][5] By pioneering automated decongestion, it influences the ecosystem through clinical trials validating superior outcomes, potential standard-of-care shifts, and partnerships (e.g., Rex Health Ventures), accelerating adoption in a space ripe for intelligent devices that enhance efficiency and economics.[2][3]
Reprieve Cardiovascular is primed for pivotal milestones, with Series B funds fueling FASTR II execution, commercial readiness, and global expansion to transform ADHF care for millions.[2] Trends like AI-driven personalization in medtech, rising HF incidence, and value-based care will propel it, potentially yielding FDA clearance and market entry by late 2020s if trial data holds. Its influence could evolve from innovator to ecosystem leader, redefining fluid management and slashing HF hospitalization burdens—echoing its mission to deliver precise, intelligent therapy where legacy treatments fall short.[1][2][3]
Reprieve Cardiovascular has raised $103.0M in total across 2 funding rounds.
Reprieve Cardiovascular's investors include David Neustaedter, Arboretum Ventures, Lightstone Ventures, Hanson S. Gifford, Cadence Capital, Genesis Capital, Anita Watkins, Sante Ventures, Deerfield Management.
Reprieve Cardiovascular has raised $103.0M across 2 funding rounds. Most recently, it raised $61.0M Series B in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2025 | $61M Series B | David Neustaedter | Arboretum Ventures, Lightstone Ventures, Hanson S. Gifford, Cadence Capital, Genesis Capital, Anita Watkins, Sante Ventures | Announced |
| Feb 1, 2024 | $42M Series A | Lightstone Ventures, Sante Ventures | Arboretum Ventures, Hanson S. Gifford, Deerfield Management, Genesis Capital | Announced |